Substitute fo	or form 1449A/PT	0		Complete if Known			
				Application Number	10/049762		
INFOF	RMATION	DISC	LOSURE	Filing Date	January 16, 2002		
STAT	EMENT E	Y AP	PLICANT	First Named Inventor	Stephen Douglas Barrett, et al.		
• • • • • • • • • • • • • • • • • • • •				Group Art Unit			
(U	se as many she	ets as ne	cessary)	Examiner Name			
Sheet	1	of	2	Attorney Docket Number	A0000100-01-SMH		

U.S. PATENT DOCUMENTS									
Examiner Initials	Cite No	U.S. Patent I Number	Cocument  Kind Code <sup>2</sup> (if known)		Date of Publication of Cited Document MM-DD-YYYY	Peges, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
19		2,502,45		Alan August Goldberg, et al.	04/04/1950				
			1						
					<u> </u>				
					<del></del>				
					ļ				
	ļ				<del> </del>				
-			<del> </del>						
ļ									
				1					
						-			
					<u> </u>				
		l							

				FOR	EIGN PATENT DOCUMENT	rs		
Examiner Initials*	Cite No Of	c e	Foreign Patent Doc	ument Kind Code <sup>5</sup> (# known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Τ¢
501		ЕP	0316630 -	Al	David T. Connor, et al.	10/26/1988		
		wo	98/37881	A1	Alexander J. Bridges	09/03/1998		
		wo	99/01421 -	Al	Stephen D. Barrett, et al	01/14/1999		
	_	wo	00/35436	A2	David T. Dudley, et al.	06/22/2000		
		wo		Al	Stephen D. Barrett, et al.	07/20/2000		
		wo	00/14505	A2	Haile Tecle, et al.	07/20/2000		
		WO	00/42002	Al	Haile Tecle	07/20/2000		
29	Z	WO	00/42003	A1	Stephen D. Barrett, et al.	07/20/2000		
						<del>                                     </del>		1

Examiner Signature	5767	Date Considered	45/04

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if (not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (08-00)
Please type a plus sign (+) inside this box 
+ + Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Cubatibut	ite for form 14498/	PTO		Complet If Known			
				Application Number	10/049762		
INFC	<b>DRMATI</b>	SID NC	CLOSURE	Filing Date	January 16, 2002		
			PPLICANT	First Named Inventor	Stephen Douglas Barrett, et al.		
SIA	LEMEN	IDIA	I I LIOANI	Group Art Unit			
	(use as mai	ny sheets as	necessary)	Examiner Name			
Sheet	2	of	2	Attorney Docket Number	A0000100-01-SMH		

٢			OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS								
	xaminer nitials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	12							
K	39		PCT International Search Report PCT/US00/18348								
1			N. S. DUESBERY, et al., "MEK Wars, a new front in the Battle Against Cancer", Nature Medicine, July 1999, pp 736-737, Vol. 5, No. 7								
			J. V. DUNCIA, et al., "MEK Inhibitors: The Chemistry and Biological Activity of U0126, Its Analogs, and Cyclization Products", Bioorganic & Medicinal Chemistry Letters, 1998, pp 2839-2844, No. 8								
ľ		H. FUJIMURA, et al., "Hydroxamic Acid Derivatives", Chemical Abstracts and Indexes, January 20, 1969, Vol. 70, No. 3 Abstract Only									
l		H. HIROSHI, et al., "Novel N-phenylanthranilic Acid Derivatives", Chemabs, 1968, Accession No. 1968:418858 Abstract Only									
			N. A. MOKHORT, "Dependence Between Structure, Anitinflammatory, Analgesic, and Antipyretic Actions in N-aromatic Derivatives of Anthranilic Acid", Chemabs, 1972, Accession No. 1972:121461 Abstract Only								
ļ	SA	8	RU-RONG JI, et al., "Nociceptive-specific Activation of ERK in Spinal Neurons Contributes to Pain Hypersensitivity", Nature Neuroscience, December 1999, pp 1114-1119, Vol. 2, No. 12								
			,								
-		_									
L				Ļ							
	Examine Signatur		Date Consider d 2/5/04	<u>Z</u>							

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Weshington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box	ح	+
---	---	---

Please type a plus sign (+) inside this box PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet of

Complete if Known					
Application Number	10/049762				
Filing Date	June 20, 2002				
First Named Inventor	Alexander James Bridges, et al.				
Group Art Unit	1614				
Examiner Name					
Attorney Docket Number	A0000100-01-SMH				

				U.S. PATENT DOCU	MENTS	
Examiner Initials*	Cite No.1	V.S. Patent Number	Nind Code <sup>2</sup>	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
500		5,155,11		David T. Connor et al.	10/13/1992	
[					1	
<b></b>						
$\vdash$		<u> </u>			<del>                                     </del>	= 10
					1	THE THE
						5 % ()
						The The
L				· · · · · · · · · · · · · · · · · · ·		307
<del></del>			-+		-	TO THE THE
<u> </u>					<del>                                     </del>	1800
		-	-   -			2
					1	9
					<del>                                     </del>	
			4		-	
					+ +-	

				FORE	IGN PATENT DOCUMENTS	5		
Examiner Initials	Cite	F	oreign Patent Do		Name of Patentee or	Date of Publication of	Pages, Columns, Lines, Where Relevant	
	No.1	Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (# known)	Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	ŀ
					· · · · · · · · · · · · · · · · · · ·			4
								╀
		<del>                                     </del>						╀
		<del></del>						╁
				$\rightarrow 1$				t
								T
								I
					<del></del>			4
<u>i</u>								╧
Examir Signat				590	/1 1 -	Date 2	15/04	

considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

•		_
Please type a plus sign (+) inside this box	→	+

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449B/PTO Application Number 10/049762 **INFORMATION DISCLOSURE** June 20, 2002 Filing Date STATEMENT BY APPLICANT Alexander James Bridges, et al. First Named Inventor 1614 Group Art Unit (use as many sheets as necessary) **Examiner Name** Attorney Docket Number of A0000100-01-SMH

Examiner  Cita  No.  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Item (book, magazine, journal, serial, sympostum, catalog, etc.), data, page(s), volume-issue number(s), published.  ALESSI, Dario R., et al., "PD 098059 Is a Specific Inhibitor of the Activation of Mitogen-activated Protein Kinase Kinase in Vitro and in Vivo", J. Biol. Chem., 1995, pp 27489-27494, Vol. 270, No. 46  HWANG, Daniel, et al., "Expression of Mitogen-Inducible Cyclooxygenase Induced by Lipopolysaccharide: Mediation through both mitogen-activated protein kinase and NF-KB signaling pathways in macrophages", Biochem Pharm, 1997, pp 87-96, Vol. 54, Issue 1  LARRIVEE, Jean-François, et al., "Role of the Mitogen-Activated Protein Kinases in the Expression of the Kipiri B1 Receptors Induced by Tissue Injury ", J Immunol, 1998, pp 1419-1426, Vol. 160, No. 3  POLAKIEWICZ, Roberto D., et al., "A Mitogen-activated Protein Kinase Pathway Is Required for μ-Opioid Receptor Desensitization", J. Biol. Chem., 1998, pp 12402-12406. Vol. 273, No. 20		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS
Kinase Kinase in Vitro and in Vivo", J. Biol. Chem., 1995, pp 27489-27494, Vol. 270, No. 46  HWANG, Daniel, et al., ""Expression of Mitogen-Inducible Cyclooxygenase Induced by Lipopolysaccharide: Mediation through both mitogen-activated protein kinase and NF-KB signaling pathways in macrophages"", Biochem Pharm, 1997, pp 87-96, Vol. 54, Issue 1  LARRIVEE, Jean-François, et al., "Role of the Mitogen-Activated Protein Kinases in the Expression of the Kipin B1 Receptors Induced by Tissue Injury ", J Immunol, 1998, pp 1419-1426, Vol. 160, No. 3  POLAKIEWICZ, Roberto D., et al., "A Mitogen-activated Protein Kinase Pathway Is Required for μ-Opioid Receptor Desensitization", J. Biol. Chem., 1998, pp 12402-12406. Vol. 273, No. 20		to main (cook, magazino, poma, sonia, symposium, caraiog, etc.), date, page(s), veiume-asses minimen(s),
Lipopolysaccharide: Mediation through both mitogen-activated protein kinase and NF-KB signaling pathways in macrophages", Biochem Pharm, 1997, pp 87-96, Vol. 54, Issue 1  LARRIVEE, Jean-François, et al., "Role of the Mitogen-Activated Protein Kinases in the Expression of the Kipin B1 Receptors Induced by Tissue Injury ", J Immunol, 1998, pp 1419-1426, Vol. 160, No. 3  POLAKIEWICZ, Roberto D., et al., "A Mitogen-activated Protein Kinase Pathway Is Required for μ-Opioid Receptor Desensitization", J. Biol. Chem., 1998, pp 12402-12406. Vol. 273, No. 20	391)	ALESSI, Dario R., et al., "PD 098059 Is a Specific Inhibitor of the Activation of Mitogen-activated Protein Kinase Kinase in Vitro and in Vivo", J. Biol. Chem., 1995, pp 27489-27494, Vol. 270, No. 46
Kipin B1 Receptors Induced by Tissue Injury ", J Immunol, 1998, pp 1419-1426, Vol. 160, No. 3  POLAKIEWICZ, Roberto D., et al., "A Mitogen-activated Protein Kinase Pathway Is Required for μ-Opioid Receptor Desensitization", J. Biol. Chem., 1998, pp 12402-12406. Vol. 273, No. 20		Lipopolysaccharide: Mediation through both mitogen-activated protein kinase and NF-KB signaling
Receptor Desensitization", J. Biol. Chem., 1998, pp 12402-12406. Vol. 273, No. 20		LARRIVEE, Jean-François, et al., "Role of the Mitogen-Activated Protein Kinases in the Expression of the Kinin B1 Receptors Induced by Tissue Injury ", J Immunol, 1998, pp 1419-1426, Vol. 160, No. 3
HECENED FEB 3 8 2003 TECH CENTER IMMIZING	39	POLAKIEWICZ, Roberto D., et al., "A Mitogen-activated Protein Kinase Pathway Is Required for μ-Opioid Receptor Desensitization", J. Biol. Chem., 1998, pp 12402-12406. Vol. 273, No. 20
CH CENTER 1800/2900		
REAL TOURS OF THE PARTY OF THE		CH CH
		TEA 8 2003
		DOPENIO
<b>l 1</b>		

\*EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in considered. Include copy of this form with next communication to applicant.

Signature

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Considered

<sup>1</sup> Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.